Supplementation with CLA: Isomer incorporation into serum lipids and effect on body fat of women

Animal studies have suggested that CLA, a natural component of meat and dairy products, may confer beneficial effects on health. However, human studies using supplementation with CLA have produced contradictory results. The aim of the present study was to further investigate the effect of CLA supplementation on human body fat, serum leptin, and serum lipids, as well as the incorporation of CLA isomers into serum lipids classes. Sixteen young healthy nonobese sedentary women received 2.1 g of CLA (divided equally between the cis,trans-9,11 and trans,cis-10,12 isomers) daily for 45 d and placebo for 45 d in a randomized double-blind crossover design. Body fat was estimated (by measurement of skinfold thickness at 10 sites), and blood was sampled at the beginning, middle, and end of the entire intervention period; an additional blood sample was obtained 2 wk thereafer. No significant differences in energy, carbohydrate, lipid, or protein intake existed between the CLA and placebo intake periods. No significant differences were found in body fat or serum leptin, TAG, total cholesterol, HDL-cholesterol, and alanine aminotransferase between CLA and placebo. The CLA isomer content of serum TAG, phospholipids, and total lipids increased 2–5 times with CLA supplementation (P<0.05). In contrast, the CLA content of cholesteryl esters did not change significantly. The period of 2 wk after the end of CLA supplementation was sufficient for its washout from serum lipids. These data indicate that supplementation with 2.1 g of CLA daily for 45 d increased its levels in blood but had no effect on body composition or the lipidemic profile of nonobese women.     

Dietary conjugated linolenic acid in relation to CLA differently modifies body fat mass and serum and liver lipid levels in rats

The present study compared the effect of dietary conjugated linolenic acid (CLNA) on body fat and serum and liver lipid levels with that of CLA in rats. FFA rich in linoleic acid, α-linolenic acid, CLA, or CLNA were used as experimental fats. Male Sprague-Dawley rats (4 wk old) were fed purified diets containing 1% of one of these experimental fats. After 4 wk of feeding, adipose tissue weights, serum and liver lipid concentrations, serum tumor necrosis factor (TNF)-α and leptin levels, and hepatic β-oxidation activities were measured. Compared with linoleic acid, CLA and, more potently, CLNA were found to reduce perirenal adipose tissue weight. The same trend was observed in the weight of epididymal adipose tissue. CLNA, but not CLA, was found to significantly increase serum and liver IG concentrations. Serum FFA concentration was also increased in the CLNA group more than in the other groups. The activity of β-oxidation in liver mitochondria and peroxisomes was significantly higher in the CLNA group than in the other groups. Thus, the amount of liver TG exceeded the ability of hepatic β-oxidation. Significant positive correlation was found between the adipose tissue weights and serum leptin levels in all animals (vs. perirenal: r=0.557, P<0.001; vs. epididymal: r=0.405, P<0.05). A less significant correlation was found between adipose tissue weights and serum TNF-α level (vs. perirenal: r=0.069, P<0.1; vs. epididymal: r=0.382, P<0.05). Although the mechanism for the specific effect of CLNA is not clear at present, these findings indicate that in rats CLNA modulated the body fat and TG metabolism differently from CLA.     

Effect of conjugated linoleic acid on body composition in mice

The effects of conjugated linoleic acid (CLA) on body composition were investigated. ICR mice were fed a control diet containing 5.5% corn oil or a CLA-supplemented diet (5.0% corn oil plus 0.5% CLA). Mice fed CLA-supplemented diet exhibited 57% and 60% lower body fat and 5% and 14% increased lean body mass relative to controls (P<0.05). Total carnitine palmitoyltransferase activity was increased by dietary CLA supplementation in both fat pad and skeletal muscle; the differences were significant for fat pad of fed mice and skeletal muscle of fasted mice. In cultured 3T3-L1 adipocytes CLA treatment (1×10⁻⁴ M) significantly reduced heparin-releasable lipoprotein lipase activity (−66%) and the intracellular concentrations of triacylglyceride (−8%) and glycerol (−15%), but significantly increased free glycerol in the culture medium (+22%) compared to control (P<0.05). The effects of CLA on body composition appear to be due in part to reduced fat deposition and increased lipolysis in adipocytes, possibly coupled with enhanced fatty acid oxidation in both muscle cells and adipocytes.     

Docosahexaenoic Acid and Eicosapentaenoic Acid Did not Alter <Emphasis Type="Italic">trans</Emphasis>-10,<Emphasis Type="Italic">cis</Emphasis>-12 Conjugated Linoleic Acid Incorporation into Mice Brain and Eye Lipids

trans 10,cis 12‐CLA has been reported to alter fatty acid composition in several non‐neurological tissues, but its effects are less known in neurological tissues. Therefore, the purpose of this study was to determine if CLA supplementation would alter brain and eye fatty acid composition and if those changes could be prevented by concomitant supplementation with docosahexaenoic acid (DHA; 22:6n3) or eicosapentaenoic acid (EPA; 20:5n3). Eight‐week‐old, pathogen‐free C57BL/6N female mice (n = 6/group) were fed either the control diet or diets containing 0.5% (w/w) t10,c12‐CLA in the presence or absence of either 1.5% DHA or 1.5% EPA for 8 weeks. CLA concentration was significantly (P < 0.05) greater in the eye but not in the brain lipids of the CLA group when compared with the control group. The sums of saturated, monounsaturated, polyunsaturated fatty acids, and n3:n6 ratio did not differ between these two groups for both tissues. The n3:n6 ratio and concentrations of 20:5n3 and 22:5n3 were significantly greater, and those of 20:4n6, 22:4n6, and 22:5n6 were lesser in the CLA + DHA and CLA + EPA groups than in the control and CLA groups for either tissue. DHA concentration was higher in the CLA + DHA group only but not in the CLA + EPA group when compared with the CLA group for both tissues. The dietary fatty acids generally induced similar changes in brain and eye fatty acid concentration and at the concentrations used both DHA and EPA fed individually with CLA were more potent than CLA alone in altering the tissue fatty acid concentration.     

Conjugated linoleic acid and chromium lower body weight and visceral fat mass in high-fat-diet-fed mice

More than half of the U.S. population has a body mass index of 25 kg/m² or more, which classifies them as overweight or obese. Obesity is often associated with comorbidities such as diabetes, cardiovascular diseases, and cancer. CLA and chromium have emerged as major dietary supplements that reduce body weight and fat mass, and increase basal metabolic rate in animal models. However, studies show that CLA induces insulin resistance in mice and in humans, whereas Cr improves insulin sensitivity. Hence, we designed the present study to examine the combined effect of CLA and Cr on body composition and insulin sensitivity in a Balb/c mice (n=10/group) model of high-fat-diet-induced obesity. CLA alone lowered body weight, total body fat mass, and visceral fat mass, the last of which decreased further with the combination of CLA and Cr. This effect was accompanied by decreased serum leptin levels in CLA-fed and CLA+Cr-fed mice, and by higher energy expenditure (EE) and oxygen consumption (OC) in CLA+Cr-fed mice. Serum levels of glucose, insulin, the pro-inflammatory cytokines, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6), as well as insulin resistance index (IRI), decreased with CLA, whereas CLA and Cr in combination had significant effects on insulin and IL-6 concentrations and IRI. In summary, CLA+Cr decreased body weight and fat mass in high-fat-diet-fed mice, which may be associated with decreased leptin levels and higher EE and OC.     

Docosahexaenoic Acid Supplementation Promotes Erythrocyte Antioxidant Defense and Reduces Protein Nitrosative Damage in Male Athletes

The aim of this study was to determine the influence of long‐term docosahexaenoic acid (DHA) dietary supplementation on the erythrocyte fatty acid profile and oxidative balance in soccer players after training and acute exercise. Fifteen volunteer male athletes (age 20.0 ± 0.5 years) were randomly assigned to a placebo group that consumed an almond‐based beverage (n = 6), or to an experimental group that consumed the same beverage enriched with DHA (n = 9) for 8 weeks. Blood samples were taken in resting conditions at the beginning and after 8 weeks of nutritional intervention and training in resting and in post‐exercise conditions. Oxidative damage markers (malonyldialdehyde, carbonyl and nitrotyrosine indexes) and the activity and protein level of antioxidant enzymes (catalase, superoxide dismutase, glutathione reductase and peroxidase) were assessed. The results showed that training increased antioxidant enzyme activities in erythrocytes. The experimental beverage increased DHA from 34.0 ± 3.6 to 43.0 ± 3.6 nmol/10⁹ erythrocytes. DHA supplementation increased the catalytic activity of superoxide dismutase from 1.48 ± 0.40 to 10.5 ± 0.35 pkat/10⁹ erythrocytes, and brought about a reduction in peroxidative damage induced by training or exercise. In conclusion, dietary supplementation with DHA changed the erythrocyte membrane composition, provided antioxidant defense and reduced protein peroxidative damage in the red blood cells of professional athletes after an 8‐week training season and acute exercise.     

Conjugated linoleic acid supplementation modified the body composition and serum leptin levels in weaning rats

Dietary supplementation with conjugated linoleic acid (CLA) may reduce body fat mass and increase lean body mass in various species. The objective of this study was to study the effects of conjugated linoleic acid (CLA) supplementation on body composition, serum leptin and triacylglycerol levels in Wistar rats. Rats received linoleic acid (group C) or conjugated linoleic acid (group AE, supplemented with AdvantEdge CLA, and group CO, supplemented with CLA One) in the concentrations of 2% of daily feed consumption. Serum leptin and triacylglycerol levels of rats were measured by means of commercial kits. After 42 days of supplementation, rats in the control group exhibited body fat contents of 53.94 +/- 6.80 g, and those in groups AE and CO had 45.43 +/- 4.86 g and 43.75 +/- 1.93 g, respectively, corresponding to a mean body fat reduction of 18%. Water, whole body protein and ash contents of rats supplemented with CLA were statistically higher relative to control group content (corresponding to a mean increasing of 7.65%; 6.5% and 12.35%, respectively). Experimental groups AE and CO, which received CLA supplementation, had statistically lower serum leptin levels (3.45 +/- 0.46 ng/mL and 3.08 +/- 0.19 ng/mL, respectively) relative to the control group (4.21 +/- 0.22 ng/mL) which received linoleic acid. Triacylglycerol levels did not change after CLA supplementation (p > 0.05). Supplementation with conjugated linoleic acid in the concentration of 2% of mean daily feed consumption was able to change body composition of rats after 42 days of experimentation.     

Modulation of body composition and immune cell functions by conjugated linoleic acid in humans and animal models: Benefits vs. risks

We have reviewed the published literature regarding the effects of CLA on body composition and immune cell functions in humans and in animal models. Results from studies in mice, hamsters, rats, and pigs generally support the notion that CLA reduced depot fat in the normal or lean strains. However, in obese rats, it increased body fat or decreased it less than in the corresponding lean controls. These studies also indicate that t10,c12-CLA was the isomer that reduced adipose fat; however, it also increased the fat content of several other tissues and increased circulating insulin and the saturated FA content of adipose tissue and muscle. Four of the eight published human studies found small but significant reductions in body fat with CLA supplementation; however, the reductions were smaller than the prediction errors for the methods used. The other four human studies found no change in body fat with CLA supplementation. These studies also report that CLA supplementation increased the risk factors for diabetes and cardiovascular disease including increased blood glucose, insulin, insulin resistance, VLDL, C-reactive protein, lipid peroxidation, and decreased HDL. Most studies regarding the effects of CLA on immune cell functions have been conducted with a mixture of isomers, and the results have been variable. One study conducted in mice with the purified c9,t11-CLA and t10,c12-CLA isomers indicated that the two isomers have similar effects on immune cell functions. Some of the reasons for the discrepancies between the effects of CLA in published reports are discussed. Although significant benefit to humans from CLA supplementation is questionable, it may create several health risks in both humans and animals. On the basis of the published data, CLA supplementation of adult human diets to improve body composition or enhance immune functions cannot be recommended at this time.     

Conjugated linoleic acid supplementation in humans--metabolic effects

Supplementation with conjugated linoleic acid (CLA) induces a number of physiological effects in experimental animals, including reduced body fat content, decreased aortic lipid deposition, and improved serum lipid profile. Controlled trials on the effects of CLA in humans have hitherto been scarce. The aim of this study was to evaluate the effects of supplementation with CLA in healthy humans on anthropometric and metabolic variables and on the fatty acid composition of serum lipids and thrombocytes. Fifty-three healthy men and women, aged 23–63 yr, were randomly assigned to supplementation with CLA (4.2 g/d) or the same amount of olive oil during 12 wk in a double-blind fashion. The proportion of body fat decreased (−3.8%, P<0.001) in the CLA-treated group, with a significant difference from the control group (P=0.050). Body weight, body mass index, and sagittal abdominal diameter were unchanged. There were no major differences between the groups in serum lipoproteins, nonesterified fatty acids, plasma insulin, blood glucose, or plasminogen activator inhibitor 1 (PAI-1). In the CLA group the proportions of stearic, docosatetraenoic, and docosapentaenoic acids increased in serum lipids and thrombocytes, while proportions of palmitic, oleic, and dihomoγ-linolenic acids decreased, causing a decrease of the estimated Δ-6 and Δ-9 and an increase in the Δ-5 desaturase activities. These results suggest that supplementation with CLA may reduce the proportion of body fat in humans and that CLA affects fatty acid metabolism. No effects on body weight, serum lipids, glucose metabolism, or PAI-1 were seen.     

Conjugated linoleic acid supplementation in humans: Effects on circulating leptin concentrations and appetite

Conjugated linoleic acid (CLA) has been demonstrated to reduce body fat in animals. However, the mechanism by which this reduction occurs is unknown. Leptin may mediate the effect of CLA to decrease body fat. We assessed the effects of 64 d of CLA supplementation (3 g/d) on circulating leptin, insulin, glucose, and lactate concentrations in healthy women. Appetite was assessed as a physiological correlate of changes in circulating leptin levels. Analysis of plasma leptin concentrations adjusted for adiposity by using fat mass as a covariate showed that CLA supplementation significantly decreased circulating leptin concentrations in the absence of any changes of fat mass. Mean leptin levels decreased over the first 7 wk and then returned to baseline levels over the last 2 wk of the study in the CLA-treated group. Appetite parameters measured at around the time when the greatest decreases in leptin levels were observed showed no significant differences between supplementation and baseline determinations in the CLA-supplemented group or between the CLA and placebo-supplemented groups. There was a nonsignificant trend for mean insulin levels to increase toward the end of the supplementation period in CLA-treated subjects. CLA did not affect plasma glucose and lactate over the treatment period. Thus, 64 d of CLA supplementation in women produced a transient decrease in leptin levels but did not alter appetite. CLA did not affect these parameters in a manner that promoted decreases of adiposity.     

Conjugated linoleic acids: Physiological effects in animal and man with special regard to body composition

Institute of Nutrition, Friedrich Schiller University of Jena, Jena, Germany In the last decade, conjugated linoleic acids (CLA) have been shown to have some beneficial (but also unfavourable) effects: anticarcinogenic properties, immune modulation, reduction of body fat and increase of lean body mass, normalisation of impaired glucose tolerance, promotion of fatty streak formation, and isomer‐specific effects. The research base on CLA has been derived almost exclusively from animal models, while some of the biological properties have been fairly well‐documented, others are still open to question. For about 5 years a lot of commercial CLA mixtures have been offered. These mixtures produced from linoleic acid‐rich oil like sunflower or safflower oil by alkali isomerization contained, besides cis‐9,trans‐11 and trans‐10,cis‐12 CLA isomers (about 20—40% of each), parts of cis,cis and trans,trans isomers as well. The quality of the recent products is significantly improved and they contain only two CLA isomers: cis‐9,trans‐11 and trans‐10,cis‐12. CLA play apparently a key role in regulating body composition. Several studies showed a reduction in body fat mass and a slight increase in lean body mass depending on the species. A possible explanation for the decrease of body fat may be a stimulation of lipolysis and a reduction of lipoprotein lipase activity in adipocytes. In adipose and muscle tissue a CLA‐stimulated increase of carnitine palmitoyltransferase activity resulting in an enhanced fatty acid oxidation was shown. There is evidence that CLA provide protection against cytokine‐induced (Tumour necrosis factor‐α, interleukin‐1) skeletal‐muscle catabolism (anabolic effect). The body composition modulating effects are most impressive in rodents and seem to become smaller in pigs and in humans. Data on humans are insufficient. Further research is essential to characterize the multifunctionality of CLA in humans, in order to identify the specific physiological mechanism of the biologically active isomers and to determine the optimal level of these isomers for beneficial effects.     

Long‐term conjugated linoleic acid supplementation in humans – effects on body composition and safety

In our contemporary adipogenic environment even modest improvements in body fat mass could be of relevance. In the last years animal and human studies have investigated the potential benefit of CLA on body composition. However, inconclusive results are often derived from short‐term studies. Long‐term intervention trials with supplemental CLA on body composition have not been reviewed exclusively up to now. Therefore, the objective of this study was to review the evidence of prolonged CLA supplementation as well as its influence on body composition in humans, and to summarize results from safety assessments of CLA intake. A literature search was performed to find intervention trials with CLA supplementation and its effects on body composition, as well as on insulin sensitivity. Only prolonged (≥12 wk) studies on body composition were included. The investigated studies indicate a modest reduction and/or prevention of regain of body fat in overweight/obese subjects. Results on the influence of CLA on insulin sensitivity are inconsistent, with newer data rather adding to the safety of CLA. Impaired insulin sensitivity by CLA remains a safety concern, yet is seemingly restricted to diabetic subjects and single‐isomer application. A meta‐a2 lysis of extended studies only is warranted to quantitatively evaluate the effects of CLA on body composition. Future research may elucidate if CLA should be considered as a marginal missing, semi‐essential nutrient in our present diet.     

Duodenal availability of conjugated linoleic acids after supplementation to dairy cow diets

The objective of the present study was to investigate the effects of a lipid‐encapsulated CLA preparation on rumen metabolism and the actual post‐ruminal bioavailability of the applied CLA isomers. In the rumen, the CLA supplementation modified the molar proportions of VFA. In period CLA‐1 the rumen fermentation shifted toward more butyric acid at the expense of acetic acid. The highest CLA supplementation resulted in increased amounts of isobutyric, isovaleric, and valeric acid. The apparent ruminal digestibility of starch increased in period CLA‐2. The ruminal protein degradation was higher after CLA supplementation, while the efficiency of the use of the RDP for microbial protein synthesis declined. The duodenal flow of trans‐10,cis‐12 CLA amounted to 16 and 5% of the intake in periods CLA‐1 and CLA‐2, respectively. The transfer of trans‐10,cis‐12 CLA from duodenum into milk was 36 and 48% in periods CLA‐1 and CLA‐2, respectively. Overall, the observed effects of the supplementation of lipid‐encapsulated CLA on the parameters of rumen metabolism were negligible. The actual low post‐ruminal bioavailability of trans‐10,cis‐12 CLA suggest that most of the applied fat supplement was biohydrogenated.     

Effects of conjugated linolenic acid and conjugated linoleic acid on lipid metabolism in mice

The effects of two isomers of conjugated linolenic acid (CLnA), α‐eleostearic acid (α‐ESA) and punicic acid (PA), on body fat and lipid metabolism were investigated, compared with a conjugated linoleic acid (CLA) mixture (primarily cis9,trans11‐ and trans10,cis12‐18:2) and α‐linolenic acid (ALA), a non‐conjugated octadecatrienoic acid, in the present study. ICR mice were fed either a control diet or one of four experimental diets supplemented with 1% α‐ESA, 1% PA, 1% CLA mixture and 1% ALA in the form of triacylglycerols (TAG) for 6 weeks. The weights of perirenal and epididymal adipose tissues were significantly decreased while the liver weight was significantly increased in mice fed CLA, compared with the control. In contrast to CLA, the tissue weights in α—ESA‐, PA‐ and ALA‐fed mice were not affected. No significant differences were observed in TAG, total cholesterol, high‐density lipoprotein and low‐density lipoprotein cholesterol levels among the five groups. The liver TAG level was significantly decreased in mice fed α‐ESA and PA while it was significantly increased in mice fed the CLA mixture. These results indicate that CLnA and CLA have differential effects on body fat mass and liver TAG levels in mice.     

Low Dietary c9t11-Conjugated Linoleic Acid Intake from Dairy Fat or Supplements Reduces Inflammation in Collagen-Induced Arthritis

Dietary cis‐9,trans‐11 (c9t11) conjugated linoleic acid (CLA) fed at 0.5 % w/w was previously shown to attenuate inflammation in the murine collagen‐induced (CA) arthritis model, and growing evidence implicates c9t11‐CLA as a major anti‐inflammatory component of dairy fat. To understand c9t11‐CLA's contribution to dairy fat's anti‐inflammatory action, the minimum amount of dietary c9t11‐CLA needed to reduce inflammation must be determined. This study had two objectives: (1) determine the minimum dietary anti‐inflammatory c9t11‐CLA intake level in the CA model, and (2) compare this to anti‐inflammatory effects of dairy fat (non‐enriched, naturally c9t11‐CLA‐enriched, or c9t11‐CLA‐supplemented). Mice received the following dietary fat treatments (w/w) post arthritis onset: corn oil (6 % CO), 0.125, 0.25, 0.375, and 0.5 % c9t11‐CLA, control butter (6 % CB), c9t11‐enriched butter (6 % EB), or c9t11‐CLA‐supplemented butter (6 % SB, containing 0.2 % c9t11‐CLA). Paw arthritic severity and pad swelling were scored and measured, respectively, over an 84‐day study period. All c9t11‐CLA and butter diets decreased the arthritic score (25–51 %, P < 0.01) and paw swelling (8–11 %, P < 0.01). Throughout the study, plasma tumor necrosis factor (TNFα) was elevated in CO‐fed arthritic mice compared to non‐arthritic (NA) mice but was reduced in 0.5 % c9t11‐CLA‐ and EB‐fed mice. Interleukin‐1β and IL‐6 were increased in arthritic CO‐fed mice compared to NA mice but were reduced in 0.5 % c9t11‐CLA‐ and EB‐fed mice through day 42. In conclusion, 0.125 % c9t11‐CLA reduced clinical arthritis as effectively as higher doses, and decreased arthritis in CB‐fed mice suggested that the minimal anti‐inflammatory levels of c9t11‐CLA might be below 0.125 %.     

Diet‐dependent occurrence of CLA isomers in rumen and duodenal digesta of slaughtered bulls

This study examined the effects of linolenic acid‐rich vs. linoleic acid‐rich feeding system on the occurrence of individual CLA isomers in the rumen and duodenum digesta of German Holstein and German Simmental bulls using Ag⁺‐HPLC/DAD. The diet affected the biosynthesis of individual CLA isomers in the rumen of the bulls of both breeds. The isomer t‐11,c‐13 CLA was detected as the most abundant isomer in the rumen of linolenic acid‐rich diet‐fed bulls, up to six times higher compared to linoleic acid‐rich diet‐fed bulls. However, the main isomer in muscle lipid, c‐9,t‐11 CLA, was produced to a low extent in the rumen of linolenic acid‐rich diet‐fed bulls compared to higher concentrations of this isomer in the rumen of linoleic acid‐rich diet‐fed bulls. The isomers t‐7,c‐9 CLA and t‐8,c‐10 CLA were not present in the rumen samples of bulls fed both diets; however, abundant t‐7,c‐9 CLA was identified in the duodenum. The CLA isomers t‐12,t‐14 CLA and t‐11,t‐13 CLA were identified as the main t,t CLA isomers in the rumen, and were significantly enhanced in the rumen of linolenic acid‐rich diet‐fed compared to linoleic acid‐rich diet‐fed bulls. In contrast to c‐9,t‐11 CLA, the t,t CLA isomers seem to be biosynthesized predominantly in the rumen, further transported via the duodenum and finally deposited in the tissue lipids mainly in linolenic acid‐rich diet‐fed bulls. This was shown earlier for muscle and subcutaneous fat samples from the same animal experiment.     

Safety of conjugated linoleic acid (CLA) in overweight or obese human volunteers

The main objective of the study was to investigate the safety of conjugated linoleic acid (CLA) in healthy volunteers. The effect of CLA on body composition was also investigated. The trial design was a randomized, double‐blind placebo controlled study including 60 overweight or obese volunteers (body mass index (BMI) 27.5—39.0 kg/m²). The subjects were divided into two groups receiving 3.4 g CLA or placebo (4.5 g olive oil) daily for 12 weeks. The safety was evaluated by analysis of blood parameters and by clinical examinations at baseline and week 12. Vital signs and adverse events were registered at baseline, week 6, and week 12. Bio Impedance Assessment was applied for body composition measurements. 55 subjects completed the study. Adverse events occurred in 10% of the subjects. No difference in adverse events or other safety parameters was found between the treatment groups. Small changes in the laboratory safety data were not regarded as clinically significant. Moreover, no clinically significant changes in vital signs were observed in any of the groups. In the CLA group, mean weight was reduced by 1.1 kg (paired t‐test p = 0.005), while mean BMI was reduced by 0.4 kg/m²(p = 0.007). However, the overall treatment effect of CLA on body weight and BMI was not significant. There were no differences found between the groups with regard to efficacy parameters. The results indicate that CLA in the given dose is a safe substance in healthy populations with regard to the safety parameters investigated.     

Consumption of c9,t11-18:2 or t10,c12-18:2 enriched dietary supplements does not influence milk macronutrients in healthy, lactating women

Substantial research suggests that the t10,c12–18:2, but not the c9,t11–18:2, isomer of conjugated linoleic acid (CLA) reduces milk fat synthesis in lactating bovine and rodent species. Because fat is the major energy-yielding component in human milk, we were interested in whether this is true for women as well. Thus, the effects of c9,t11–18:2 and t10,c12–18:2 on milk fat were examined in breast-feeding women (n = 12) in a double-blind, placebo-controlled, crossover study with latin-square design. The study was divided into six periods: baseline (3 days), three intervention periods (5 days each), and two washout periods (9 days each). During each intervention period, women consumed 750 mg/day of a supplement containing predominantly c9,t11–18:2, t10,c12–18:2, or 18:1 (olive oil placebo). Milk was collected by complete breast expression on the final day of each period. Infant milk consumption was estimated by 24 h weighing on the penultimate day of each intervention and washout period, and maternal adiposity (% body fat) was determined at baseline using dual energy X-ray absorptiometry. Milk c9,t11–18:2 and t10,c12–18:2 concentrations were greater (P < 0.05) during the corresponding CLA treatment periods as compared to the placebo period, providing strong evidence of subject compliance. Both CLA isomers were transferred into milk fat at relatively high efficiency; average transfer efficiency was estimated to be 23.3%. Compared to the placebo treatment, milk fat content was not reduced during either CLA treatment. Data indicate that body fatness did not modify any putative effect of isomeric CLA consumption on milk fat concentration. The evidence from this study suggests that the sensitivity of lactating women’s mammary tissue to an anti-lipogenic effect of the t10,c12–18:2 isoform of CLA may be less than previously hypothesized.     

Conjugated Linoleic Acid Isomers, t10c12 and c9t11, are Differentially Incorporated into Adipose Tissue and Skeletal Muscle in Humans

Conjugated linoleic acid (CLA) is a popular supplement believed to enhance immune function, body composition and insulin sensitivity, but results of scientific studies investigating its effects are conflicting. The isomer- and tissue-specific effects of CLA may explain these conflicting results. Therefore, this study quantified the incorporation of the c9t11 and t10c12 CLA isomers into adipose tissue and skeletal muscle in response to supplementation in healthy, regularly-exercising, non-obese persons. The CLA group (n = 14) ingested 3.9 g per day CLA (50:50 t9c11:c10t12) and the placebo group (n = 11) 3.9 g per day high-oleic-acid sunflower oil for 12 weeks. Following supplementation, the t10c12 isomer was incorporated into adipose tissue triacylglycerol (P < 0.001), and the c9t11 isomer tended to increase in skeletal muscle phospholipids (P = 0.056). Therefore, human adipose tissue and skeletal muscle are enriched with CLA in an isomer-specific manner.     

Supplemental Conjugated Linoleic Acid Consumption Does Not Influence Milk Macronutrient Contents in all Healthy Lactating Women

The term “conjugated linoleic acid” (CLA) refers to a group of positional and geometric isomers that are derived from linoleic acid and are found primarily in meat and milk products from ruminant animals. Due to the array of putative benefits associated with various forms of CLA, there has been recent interest in supplementing human diets with these fatty acids especially when weight loss is desired. However, in many animal models, CLA has been shown to decrease milk fat production. There is some concern, therefore, that maternal CLA supplementation during lactation might inadvertently decrease nutrient supply to the nursing infant. However, there is only limited research on the effect of CLA consumption on milk fat content in women. Based on previously published work from our laboratory, we hypothesized that CLA supplementation would reduce the milk fat percentage in lactating women in a dose-dependent manner. Breastfeeding women (n = 12) were assigned randomly to treatments of 4 g/day safflower oil (SFO), 2 g/day CLA plus 2 g/day SFO, or 4 g/day CLA in a double blind, 3 × 3 Latin square design. Conjugated linoleic acid supplements contained approximately equal amounts of cis9,trans11–18:2 and trans10,cis12–18:2; the two most common isoforms of CLA. Milk was collected by complete breast expression on the last day (day 5) of each intervention period and analyzed for macronutrient and fatty acid composition. On day 4 of each intervention period, infant milk consumption was estimated by 24 h weighing of the infant. Washout periods were 9 days in length. We observed a dose-dependent increase in the concentrations of cis9,trans11–18:2 and trans10,cis12–18:2 in the milk fat. However, we detected neither a change in overall macronutrient composition nor infant milk consumption. These data do not support those obtained from animal models or our previous human work suggesting that consumption of CLA mixtures necessarily reduces milk fat. It is possible that either (1) the interpretation of our previously published data should be reevaluated, and/or (2) there are important intra- and inter-species differences in this regard.